NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

Phase 1

Active, not recruiting

Conditions: Metastatic Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Edodekin alfa
Procedure: Magnetic Resonance Imaging
Biological: Pembrolizumab
Procedure: Positron Emission Tomography

First Posted Date: 2017-01-25

Last Posted Date: 2025-04-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT03030378

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States
🇺🇸
University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States

and more 24 locations

Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas

Phase 1

Completed

Conditions: Solid Tumors
Lymphoma

Interventions: Drug: LMP744
Other: Ondansetron
Other: Olanzapine
Other: Lorazepam
Other: Diphenoxylate hydrocholoride (HCL) + Atropine Sulfate
Other: Loperamide
Other: Diphenhydramine
Other: Steroid
Other: Epinephrine

First Posted Date: 2017-01-25

Last Posted Date: 2024-12-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT03030417

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma

Phase 2

Completed

Conditions: Oligodendrogliomas
Astrocytoma, Grades II, III and IV
Glioblastoma Multiforme
Giant Cell Glioblastoma
Glioma

Interventions: Drug: LB-100

First Posted Date: 2017-01-23

Last Posted Date: 2023-11-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 7

Registration Number: NCT03027388

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Prospective Evaluation and Molecular Profiling in People With Gastric Tumors

Completed

Conditions: Stomach Cancer
Stomach Neoplasms

First Posted Date: 2017-01-23

Last Posted Date: 2025-02-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 250

Registration Number: NCT03027427

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Integrating Use of Self-Affirmation Content Into a Mobile App to Promote Quit Attempts With Text-Based Smoking Cessation Intervention Messaging

Not Applicable

Completed

Conditions: Number of Quit Attempts

Interventions: Behavioral: Self-affirmation induction

First Posted Date: 2017-01-23

Last Posted Date: 2021-07-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 7899

Registration Number: NCT03027466

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics

Withdrawn

Conditions: Adenomatous Polyposis Coli
Neurofibroma, Plexiform
Neoplasms
Myelodysplastic Syndromes

First Posted Date: 2017-01-23

Last Posted Date: 2020-10-08

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT03027401

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)

Phase 2

Terminated

Conditions: Glioblastoma

Interventions: Drug: Pembrolizumab
Biological: HSPPC-96
Drug: Temozolomide
Procedure: Surgery
Other: Placebo

First Posted Date: 2017-01-12

Last Posted Date: 2025-02-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 90

Registration Number: NCT03018288

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer

Early Phase 1

Completed

Conditions: FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma
FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma

Interventions: Drug: Entinostat
Procedure: Hysterectomy
Other: Laboratory Biomarker Analysis
Drug: Medroxyprogesterone Acetate

First Posted Date: 2017-01-12

Last Posted Date: 2021-11-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT03018249

Locations: 🇺🇸
The Mark H Zangmeister Center, Columbus, Ohio, United States
🇺🇸
UPMC-Saint Clair Hospital Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸
John Muir Medical Center-Concord Campus, Concord, California, United States

and more 231 locations

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

Phase 1

Active, not recruiting

Conditions: Recurrent Gastroesophageal Junction Adenocarcinoma
Stage III Esophageal Cancer AJCC v7
Metastatic Gastric Carcinoma
Recurrent Esophageal Carcinoma
Stage III Gastric Cancer AJCC v7
Stage IV Esophageal Cancer AJCC v7
Metastatic Esophageal Carcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma
Unresectable Esophageal Carcinoma
Unresectable Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Olaparib
Biological: Ramucirumab

First Posted Date: 2017-01-02

Last Posted Date: 2025-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 51

Registration Number: NCT03008278

Locations: 🇺🇸
City of Hope Antelope Valley, Lancaster, California, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
City of Hope Upland, Upland, California, United States

and more 29 locations

CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer

Phase 2

Terminated

Conditions: Thyroid Neoplasms
Poorly Differentiated and Undifferentiated Thyroid Cancer
Differentiated Thyroid Cancer

Interventions: Drug: CUDC-907

First Posted Date: 2016-12-26

Last Posted Date: 2018-12-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 7

Registration Number: NCT03002623

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy